Funding for this research was provided by:
Taiho Pharmaceutical Co., Ltd.
Article History
Received: 24 October 2022
Accepted: 2 March 2023
First Online: 13 March 2023
Declarations
:
: Dr Naito has received grants or contracts (to their institution) from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eisai Co., Eli Lilly, Ono, Pfizer and Taiho Pharmaceutical Co., Ltd; and payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Bristol Myers Squibb, Chugai Pharma, Eisai, Eli Lilly, FUJIFILM Toyama Chemistry, Gardant, Mundi, Novartis, Ono, Pfizer, Shionogi, Taiho Pharmaceutical Co., Ltd. and Takeda. Dr Nishida has received honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Eisai Co., Otsuka, Pfizer and Taiho Pharmaceutical Co., Ltd. Dr Doi has received grants or contracts (to their institution) from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharma, Daiichi Sankyo, Eisai Co., Eli Lilly, IQVIA, Janssen Pharma, MSD, Merck Biopharma, Novartis, Pfizer, Sumitomo Dainippon and Taiho Pharmaceutical Co., Ltd; consulting fees from AbbVie, Bayer, Chugai Pharma, Kaken Pharma, Kyowa Kirin, Otsuka Pharma, PRA Health Sciences, Rakuten Medical, Shionogi, Sumitomo Dainippon, Takeda and Taiho Pharmaceutical Co. Ltd; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Ono Pharma and Rakuten Medical; and participated on a data safety monitoring board or advisory board for AbbVie, Amgen, Astellas Pharma, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Janssen Pharma, MSD and Novartis.